Lymphodepletion Therapy

PROCEDURE4 trials

Sponsors

City of Hope Medical Center, Fred Hutchinson Cancer Center

Conditions

Acute Myeloid LeukemiaCastration-Resistant Prostate CarcinomaHigh Grade B-Cell Non-Hodgkin's LymphomaIntermediate Grade B-Cell Non-Hodgkin's LymphomaMetastatic Prostate CarcinomaRecurrent Adult Acute Myeloid LeukemiaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma

Phase 1

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

RecruitingNCT05672147

City of Hope Medical CenterAcute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia +1

Start: 2023-12-07End: 2028-09-03Target: 27Updated: 2026-03-05

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

RecruitingNCT05801913

City of Hope Medical CenterHigh Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma +1

Start: 2023-09-29End: 2028-12-30Target: 15Updated: 2026-03-05

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT05805371

City of Hope Medical CenterCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2024-07-19End: 2028-11-11Target: 21Updated: 2025-11-19

ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

RecruitingNCT07098364

Fred Hutchinson Cancer CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma +9

Start: 2025-12-27End: 2043-10-04Target: 33Updated: 2026-01-14

Related Papers

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial.

2024-06-1259 citations

A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2024-06-013 citations